Projects

Anti-Coronavirus Therapies (ACT) to prevent progression of mild COVID-19

Project Description

Librexia AF is a randomized, double-blind, double-dummy, parallel group, active-controlled study to evaluate the efficacy and safety of milvexian versus apixaban in participants with atrial fibrillation. Librexia AF is a randomized, double-blind, double-dummy, parallel group, active-controlled study to evaluate the efficacy and safety of milvexian versus apixaban in participants with atrial fibrillation.Librexia AF is a randomized, double-blind, double-dummy, parallel group, active-controlled study to evaluate the efficacy and safety of milvexian versus apixaban in participants with atrial fibrillation.

Project Duration

2021 - 2023

Project Lead

Dr. Shruthi M Kulkarni

Authors

Dr. Shruthi M Kulkarni, Dr. B Ramakrishna Goud, Dr. Farah Naaz Fathima, Dr. Pooja R Sridhar

Project Status

completed

Project Type

Population Health Research Institute, Hamilton Health Sciences Research Institute funded international multicenter drug trial